User Image Cart Icon 0 Search Image

Silybin (Milk Thistle)

  1. A comparative study on enzyme kinetics of diastereoisomeric silybin A and silybin B glucuronidation in rat liver microsome
  2. A comparative study on the stability of silybin and that in silymarin in buffers and biological fluids.
  3. A Comparison of Spray-Drying and Freeze-Drying for the Production of Stable silybin Nanosuspensions
  4. A comparison of the diastereoisomers, silybin A and silybin B, on the induction of apoptosis in K562 cells
  5. A long-term treatment with silybin in patients with non-alcoholic steatohepatitis stimulates catalase activity in human endothelial cells
  6. A new drug nanocrystal self-stabilized Pickering emulsion for oral delivery of silybin
  7. A New Pro-Prodrug Aminoacid-Based for Trans-Ferulic Acid and silybin Intestinal Release
  8. A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations
  9. A novel approach for the efficient extraction of silybin from milk thistle fruits
  10. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
  11. A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma
  12. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis.
  13. A presurgical study of oral silybin-phosphatidylcholine in patients with early breast cancer
  14. A randomized multicentre double-blind vs placebo trial: Evaluation of effect of silybin conjugated with phosphatidilcholine and vitamin E on liver damage in patients …
  15. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos).
  16. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis
  17. A silybin-phospholipids complex counteracts rat fatty liver degeneration and mitochondrial oxidative changes
  18. A Simple HPLC Method for the Quantitative Determination of silybin in Rat Plasma: Application to a Comparative Pharmacokinetic Study on Commercial Silymarin …
  19. A study of high‐dose oral silybin‐phytosome followed by prostatectomy in patients with localized prostate cancer
  20. Ability of silybin and its derivatives to prevent protein oxidation in different model systems
  21. Absorption characteristics of silybin-phospholipid complex by rat intestine.
  22. Abstract A58: Green tea and silybin for breast cancer: A pilot presurgical study
  23. Abstract# 4510: A pilot study of oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer
  24. Acetaminophen does not induce oxidative stress in isolated rat hepatocytes: its probable antioxidant effect is potentiated by the flavonoid silybin
  25. Activation of sirtuin 3 by silybin attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury
  26. ADME/Tox Properties and Biochemical Interactions of silybin Congeners: In silico Study
  27. Advances in Chemical Modification of silybin and Its Analogues.
  28. Advances in the Researches on Derivatives of silybin [J]
  29. Alterations in insulin receptor in injured rats and the effects of dexamethasone and silybin
  30. Ameliorative effect of silybin on bisphenol A induced oxidative stress, cell proliferation and steroid hormones oxidation in HepG2 cell cultures
  31. Anti-cancer efficacy of silybin derivatives-a structure-activity relationship
  32. Anti-inflammatory effects of silybin and Thioctic acid in lipopolysaccharide (LPS)-induced BV-2 murine microglia
  33. Antioxidant activity of silybin and 2, 3-dehydrosilybin from Silybum marianum (L). Gaertn. Fruits
  34. Antioxidant activity of silybin in vivo during long-term iron overload in rats
  35. Antioxidant and antiviral activities of silybin fatty acid conjugates
  36. Antioxidant properties of silybin glycosides
  37. Antioxidant properties of the flavonoids silybin and (+)-cyanidanol-3: comparison with butylated hydroxyanisole and butylated hydroxytoluene
  38. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin
  39. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer
  40. Apoptosis effect of HepG2 cell induced by silybin-phosphatidylcholine compound [J]
  41. Aquaporin-9 is involved in the lipid-lowering activity of the nutraceutical silybin on hepatocytes through modulation of autophagy and lipid droplets composition
  42. Baicalein enhances the oral bioavailability and hepatoprotective effects of silybin through inhibiting efflux transporters BCRP and MRP2
  43. Base-catalyzed oxidation of silybin and isosilybin into 2, 3-dehydro derivatives
  44. Bax/tubulin/epithelial-mesenchymal pathways determine the efficacy of silybin analog HM015k in colorectal cancer cell growth and metastasis
  45. Benzodioxans by oxidative phenol coupling. Synthesis of silybin
  46. Bile-salt effect on the dissociation of silybin
  47. Bioavailability of a silybin–phosphatidylcholine complex in dogs
  48. Biocatalytic synthesis and antitumor activities of novel silybin acylated derivatives with dicarboxylic acids
  49. Bioconversion of silybin to phase I and II microbial metabolites with retained antioxidant activity
  50. Biomimetic synthesis of natural silybin
  51. Biotransformation of silibinin (silybin) using fungal organisms
  52. Biotransformation of silybin and its congeners
  53. Changes of gut microbiota during silybin mediated treatment of high‐fat diet‐induced nonalcoholic fatty liver diseasein mouse
  54. Changes of liver microsomal drug-metabolizing system and lipoperoxidation activity in scalded rats and the effects of silybin
  55. CHANGES OF LIVER MICROSOMAL DRUG-METABOLIZING SYSTEM AND LIPOPEROXIDATION ACTIVITY IN SCALDED RATS AND THE EFFECTS OF silybin [J]
  56. Characterizing the properties of anticancer silibinin and silybin B complexes with UV–Vis, FT-IR, and Raman spectroscopies: A combined experimental and theoretical …
  57. Chemistry of silybin
  58. Chemoenzymatic preparation of silybin β-glucuronides and their biological evaluation
  59. Chemo-enzymatic synthesis of silybin and 2, 3-dehydrosilybin dimers
  60. Chromato-spectrophotometric method for the quantitative determination of silybin in Silybum marianum fruits.
  61. Clinical curative effect and safety of Silybin-nanosuspension in the treatment of liver tumor
  62. Clinical Efficacy of Combined Ginkgo Leaf and silybin in the Treatment of Nonalcoholic Fatty Liver Diseases
  63. Clinical efficacy of silybin in 168 patients with fatty liver
  64. Clinical observation of PHGF joint water silybin in treatment of anti-TB drugs cause liver damage [J]
  65. Clinical Observation on Treatment of Alcoholic Fatty Liver with Xiaozhi Huoxue Oral Liquid and silybin Meglumine Tablet
  66. Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency
  67. Combination of taurine with silybin meglumine in treatment of patients with non-alcohlic steatohepatitis
  68. Combinational applicaton of silybin and tangeretin attenuates the progression of non-alcoholic steatohepatitis (NASH) in mice via modulating lipid metabolism
  69. Comparative effect of silymarin and silybin treatment on inflammation and oxidative stress in transgenic spontaneously hypertensive rats overexpressing human C …
  70. Comparative study of the hepatoprotective effect of silymarin and silybin on isolated rat hepatocytes
  71. Comparative study on optimization of silybin particles preparation by uniform design and orthogonal design
  72. Comparative treatment of α-amanitin poisoning with N-acetylcysteine, benzylpenicillin, cimetidine, thioctic acid, and silybin in a murine model
  73. Comparing studies of silybin metabolism in normal rats and liver injury model rats
  74. Comparing the effect of silybin and silybin advanced™ on viability and HER2 expression on the human breast cancer SKBR3 cell line by no serum starvation
  75. Comparison and improvement of two methods for refining silybin
  76. Comparison of the in vitro antifibrogenic effects of silymarin, silybin a and 18α-glycyrrhizin on activated hepatic stellate cells
  77. Constituents of Silybum marianum. Structure of isosilybin and stereochemistry of silybin
  78. Content analysis of silybin in Yiganling tablets by RP-HPLC
  79. Correction to: Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy …
  80. Curative effect of lamivudine and silybin-lecithin compound on 88 patients with chronic hepatitis B [J]
  81. Curative effect of silybin combined with pituitrin-phentolamine for pulmonary tuberculosis complicated by acute hemoptysis
  82. Curcumin, silybin Phytosome® and α‐R‐Lipoic Acid Mitigate Chronic Hepatitis in Rat by Inhibiting Oxidative Stress and Inflammatory Cytokines Production
  83. Current status of pharmacokinetics and clinical study of silybin-phospholipid complex
  84. Cytoprotective effect of silybin against lasalocid-induced toxicity in HepG2 cells
  85. Cytotoxicity of monensin, narasin and salinomycin and their interaction with silybin in HepG2, LMH and L6 cell cultures
  86. Dehydrosilybin is a better DNA topoisomerase I inhibitor than its parental silybin
  87. DEPRESSANT EFFECT OF SILYBIN-PHOSPHATIDYLCHOLINE COMPOUND (SPC) ON ADVANCED GLYCATION END PRODUCTS (AGEs) IN ALLOXAN …
  88. DERIVATIVES OF NATURAL 2, 3-DEHYDRO-silybin AS ANGIOGENESIS MODULATORS
  89. Design and discovery of silybin analogues as antiproliferative compounds using a ring disjunctive–Based, natural product lead optimization approach
  90. Design and Pharmacological Development of Novel silybin Analogues as Potent and Selective Antiproliferative Agents
  91. Design, optimization and in vitro-in vivo evaluation of smart nanocaged carrier delivery of multifunctional PEG-chitosan stabilized silybin nanocrystals
  92. Design, synthesis, and examination of neuron protective properties of alkenylated and amidated dehydro-silybin derivatives
  93. Determination of concentration and encapsulation efficiency of silybin liposomes
  94. Determination of content of silubin in silybin capsule by HPLC
  95. Determination of entrapment efficiency and drug phase distribution of submicron emulsions loaded silybin
  96. Determination of Residual Organic Solvent in Silybin-N-Meglumine by Headspace GC [J]
  97. Determination of silybin B in the Different Parts of Silybum marianum using HPLC-UV
  98. Determination of silybin in beagle dog plasma by LC/MS
  99. Determination of silybin in blood plasma using high performance liquid chromatography with solid phase extraction
  100. Determination of silybin in Fufang Yiganling Tablet by HPLC [J]
  101. Determination of silybin in health food by high performance liquid chromatography
  102. Determination of silybin in human plasma by HPLC
  103. Determination of silybin in human plasma by RP-HPLC
  104. Determination of silybin in Silymarin and its Preparations by HPLC
  105. Determination of silybin in the rat plasma by RP-HPLC [J]
  106. Determination of silybin in Yiganning Dispersible Tablets by HPLC
  107. Determination of silybin of Nutraceutical Herbal Preparations Using HPLC-PDA
  108. Determination of the Content and Entrapment Efficiency of silybin Nanostructured Lipid Carrier [J]
  109. Determination of the entrapment efficiency of silybin liposomes by first derivative spectrometry
  110. Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers
  111. Differential effect of silybin on the Fe2+-ADP and t-butyl hydroperoxide-induced microsomal lipid peroxidation
  112. Differential effects of the flavonolignans silybin, silychristin and 2, 3-dehydrosilybin on Mesocestoides vogae larvae (cestoda) under hypoxic and aerobic in …
  113. Differential transcriptional profiles in HepG2 cells after the exposure to a chemically characterized complex preparation of Silybi mariani fructus and its chemically defined constituent silybin A + B
  114. Dimerisation Process of Silybin‐Type Flavonolignans: Insights from Theory
  115. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth
  116. Does silybin protect against toxicity induced by polymyxin E in rat kidney?
  117. Down-regulation of LPCAT expression increases platelet-activating factor level in cirrhotic rat liver: potential antiinflammatory effect of silybin
  118. Effect of 3‐O‐Galloyl Substitution on the Electrochemical Oxidation of Quercetin and silybin Galloyl Esters at Glassy Carbon Electrode
  119. Effect of Absorption Enhancers on Intestinal Absorption of silybin and its Phospholipid Complex [J]
  120. Effect of flavonolignans derived from silybin on mitochondrial production of reactive oxygen species
  121. EFFECT OF GIBBERELLIC ACID (GA) AND METHANOL SPRAYING ON silybin YIELD IN SILYBUM MARIANUM (L.) GAERTN
  122. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities
  123. Effect of silybin and its glycosides on the expression of cytochromes P450 1A2 and 3A4 in primary cultures of human hepatocytes
  124. Effect of silybin Capsule on Vascular Endothelial Function in Patients with Non-alcoholic Fatty Liver Disease
  125. Effect of silybin dihemisuccinate on the ethanol metabolizing systems of the rat liver
  126. Effect of silybin meglumine Tablets on Treatment of Nonalcoholic Steatohepatitis in Rats [J]
  127. Effect of silybin on biliary lipid composition in rats
  128. Effect of silybin on Coxsackie B_5 Virus Infected New Born Rat Heart Cells in Culture
  129. Effect of silybin on Coxsackie B_5 Virus Infected New Born Rat Heart Cells in Culture [J]
  130. Effect of silybin on hepatic cell membranes after damage by polycyclic aromatic hydrocarbons (PAH).
  131. Effect of silybin on high-fat-induced fatty liver in rats
  132. Effect of silybin on lipid profile in hypercholesterolaemic rats
  133. Effect of silybin on phalloidin-actin interactions in vitro
  134. Effect of silybin on phorbol myristate actetate-induced protein kinase C translocation, NADPH oxidase activity and apoptosis in human neutrophils
  135. Effect of silybin on proliferation and remodeling of vessels after balloon injury
  136. Effect of silybin on the fibrillation of hen egg‐white lysozyme
  137. Effect of silybin on the fibrogenic cytokines production by mouse peritoneal macrophages [J]
  138. Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice
  139. Effects of lamivudine combining with silybin on secondary cirrhosis induced by hepatitis B
  140. Effects of Mediterranean diet supplemented with silybin–vitamin E–phospholipid complex in overweight patients with non-alcoholic fatty liver disease
  141. Effects of silybin on acute myocardial infarction and reperfusion injury in anesthetized rats
  142. Effects of silybin on histamine release from human basophil leucocytes.
  143. EFFECTS OF silybin ON ISOLATED RABBIT PORTAL VEIN AND THORACIC AORTA
  144. Effects of silybin on mitochondria membrane fluidity in rats with non-alcoholic fatty liver disease
  145. Effects of silybin on Neointimal Proliferation of Rabbit Iliac Artery after Balloon Injury [J]
  146. Effects of silybin on production of oxygen free radical, lipoperoxide and leukotrienes in brain following ischemia and reperfusion
  147. Effects of silybin on red blood cell sorbitol and nerve conduction velocity in diabetic patients
  148. EFFECTS OF silybin ON REPERFUSION-INDUCED ARRHYTHMIAS AND SUPEROXIDE ANION RADICAL [J]
  149. Effects of Silybin-phospholipid Complex on Inflammatory Factors of Autoimmune Prostatitis in Rats
  150. Effects of silymarin and silybin on lipoprotein cholesterol levels and oxidizability of low density lipoproteins in rats
  151. Effects of silymarin flavonolignans and synthetic silybin derivatives on estrogen and aryl hydrocarbon receptor activation
  152. Electrospun silybin Enriched Scaffolds of Polyethylene Oxide as Wound Dressings: Enhanced Wound Closure, Reepithelization in Rat Excisional Wound …
  153. Engineered silybin nanoparticles educe efficient control in experimental diabetes
  154. Engineering enzymatic cascades for the efficient biotransformation of eugenol and taxifolin to silybin and isosilybin
  155. Enhanced bioactivity of silybin B methylation products
  156. Enhanced oral bioavailability of silybin by a supersaturatable self-emulsifying drug delivery system (S-SEDDS)
  157. Enhancement of oral bioavailability of the poorly water-soluble drug silybin by sodium cholate/phospholipid-mixed micelles
  158. Enterohepatic Recirculation of Free and Conjugated silybin Following Administration of a Chewing Gum with Milk Thistle Extract I. Grabnar (1), M. Pišlar (1), L. Maggi …
  159. Enzymatic and Metabolic Transformation of silybin and its Congeners
  160. Enzymatic kinetic resolution of silybin diastereoisomers
  161. Enzymatic preparation of acylated derivatives of silybin in organic and ionic liquid media and evaluation of their antitumor proliferative activity
  162. Enzymatic preparation of silybin phase II metabolites: sulfation using aryl sulfotransferase from rat liver
  163. Establishment and application of an experimental model of human fetal hepatocytes for investigation of the protective effects of silybin and polyporus umbellalus polysaccharides
  164. Establishment of culture system of Silybum marianum hairy roots and determination of silybin
  165. Establishment of Silybum marianum cell suspension culture system and effects of different factors on silybin content
  166. Eudragit nanoparticles loaded with silybin: a detailed study of preparation, freeze-drying condition and in vitro/in vivo evaluation
  167. Evaluation of the Effect Derived from silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters …
  168. Evaluation of the genotoxic and anti-genotoxic activities of silybin in human hepatoma cells (HepG2)
  169. Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP …
  170. Excess fructose and fatty acids trigger a model of non‑alcoholic fatty liver disease progression in vitro: Protective effect of the flavonoid silybin
  171. Experimental study of silybin-phospholipid complex intervention on amiodarone-induced fatty liver in mice
  172. Extraction of oil and silybin compounds from milk thistle seeds using supercritical carbon dioxide
  173. Fast repair activities towards dGMP hydroxyl radical adducts by silybin and its analogues
  174. Flavonoid silybin improves the response to radiotherapy in invasive bladder cancer
  175. Formulation and development of silybin loaded solid lipid nanoparticle enriched gel for irritant contact dermatitis
  176. Formulation development and characterization of silybin loaded nanoparticles
  177. Formulation of perspective hepatoprotector polymeric forms based on silybin and ursodeoxycholic acid
  178. Free radical scavenging reactions and antioxidant activities of silybin: mechanistic aspects and pulse radiolytic studies
  179. Free‐radical scavenging activities of silybin and its analogues: A pulse radiolysis study
  180. Glycosylation of silybin
  181. Gram-positive bacteria specific properties of silybin derived fromSilybum marianum
  182. he flavano-lignan flavanone derivatives silandrin, silybin and silychristin from Silibum marianum (Asteraceae) are antihepatotoxic. Sanggenon C and sanggenon D bind to the phorbol ester binding site on protein kinase C (PKC). Dihydroflavonols
  183. Heat capacity for the binary system of silybin and poly (vinylpyrrolidone) K30
  184. Heat Capacity for the Binary System of silybin and Sodium Cholate
  185. Hepatoprotective Activity of Xanthones and Xanthonolignoids Against tert-Butylhydroperoxide-Induced Toxicity in Isolated Rat Hepatocytes—Comparison with Silybin
  186. Hepatoprotective and antifibrotic effect of a new silybin–phosphatidylcholine–vitamin E complex in rats
  187. Hepatoprotective effects of S‐adenosylmethionine and silybin on canine hepatocytes in vitro
  188. HiFSA fingerprinting applied to isomers with near-identical NMR spectra: the silybin/isosilybin case
  189. High-Affinity Binding of silybin Derivatives
  190. High-affinity binding of silybin derivatives to the nucleotide-binding domain of a Leishmania tropicaP-glycoprotein-like transporter and chemosensitization of a …
  191. Highly sensitive detection of silybin based on adsorptive stripping analysis at single-sided heated screen-printed carbon electrodes modified with multi-walled carbon …
  192. HM015k, a novel silybin derivative, multi-targets metastatic ovarian cancer cells and is safe in zebrafish toxicity studies
  193. How the presence of metal atoms and clusters can modify the properties of Silybin? A computational prediction
  194. HPLC-MS/MS study on pharmacokinetics of silybin A and silybin B in rat plasma
  195. Identification and initial SAR of silybin: an Hsp90 inhibitor
  196. Identification of 23-(s)-2-amino-3-phenylpropanoyl-silybin as an antiviral agent for influenza A virus infection in vitro and in vivo
  197. Improving bioavailability of silybin by inclusion into SBA-15 mesoporous silica materials
  198. In vitro and in vivo evaluation of silybin nanoparticles for liver cancer
  199. In vitro and in vivo evaluation of silybin nanosuspensions for oral and intravenous delivery
  200. In vitro antitumor activity of silybin nanosuspension in PC-3 cells
  201. In vitro inhibitory effects of major bioactive constituents of Andrographis paniculata, Curcuma longa and Silybum marianum on human liver microsomal morphine glucuronidation: A prediction of potential herb-drug interactions arising from andrographolide, curcumin and silybin inhibition in humans
  202. In Vitro Micropropagation of Silybum marianum L from Various Explants and silybin Content
  203. In Vitro Release and Bioavailability of silybin from Micelle-Templated Porous Calcium Phosphate Microparticles
  204. In vitro release and in vitro–in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles
  205. In vivo absorption comparison of nanotechnology-based silybin tablets with its water-soluble derivative
  206. In vivo evaluation of silybin nanosuspensions targeting liver
  207. In vivo fate of lipid-silybin conjugate nanoparticles: implications on enhanced oral bioavailability
  208. Increase in rat liver synthesis of fatty acids and glycerol phospholipids following parenteral application of silybin-dihemisuccinate
  209. Influence of Expression of Intercellular Adhesion Molecule-1 on Cerebral Ischemic Reperfusion Injury and Cerebral Protective of Silybin-lecithin Compound in …
  210. Influence of silybin on biophysical properties of phospholipid bilayers1
  211. Influence of silybin on hepatic fibrosis indexes in patients with chronic hepatitis B
  212. Influence of Silybin-dihemisuccinate on fatty acid synthesis in rat liver (author’s transl)
  213. Inhibition of glucose uptake by silybin and Dehydrosilybin
  214. Inhibition of rat liver cytosolic glutathione S-transferase by silybin
  215. Inhibition of SIRT1 signaling sensitizes the antitumor activity of silybin against human lung adenocarcinoma cells in vitro and in vivo
  216. Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro
  217. Inhibitory effect of silybin on the activity of 5-lipoxygenase of the porcine cerebral basilar artery
  218. Inhibitory Effect of Silybin-Phosphatidylcholine Compound on the Activation of Nuclear Factor-? B and Phosphorylation of Inhibitors of Nuclear Factor-? B? in …
  219. Inhibitory Effect of Silybin-Phosphatidylcholine Compound on the Activation of Nuclear Factor-kappa B and Phosphorylation of Inhibitors of Nuclear Factor-kappa B …
  220. Inhibitory effects of silybin on the efflux pump of methicillin‑resistant Staphylococcus aureus
  221. Investigation on the binding interaction between silybin and pepsin by spectral and molecular docking
  222. Investigations on the actions of silybin on regenerating rat liver. Effects on Kupffer’s cells.
  223. In-Vitro Activity of silybin and Related Flavonolignans against Leishmania infantum and L. donovani
  224. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin
  225. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin
  226. Is silybin the best free radical scavenger compound in silymarin?
  227. Isolation and purification of silychristin, silydianin and taxifolin in the co-products of the silybin refined process from the silymarin by high-speed counter-current …
  228. Isolation of diastereoisomers from silybin and determination silybin by HPLC [J]
  229. IV-23 Iztok Grabnar Enterohepatic Recirculation of Free and Conjugated silybin Following Administration of a Chewing Gum with Milk Thistle Extract
  230. Laccase-mediated dimerization of the flavonolignan silybin
  231. Large-scale separation of silybin diastereoisomers using lipases
  232. Laser photolysis and pulse radiolysis studies on silybin in ethanol solutions
  233. Linear regression analysis of silychristin A, silybin A and silybin B contents in Silybum marianum
  234. Lipid peroxidation and irreversible damage in the rat hepatocyte model: protection by the silybin-phospholipid complex IdB 1016
  235. Liquid chromatographic assay of silybin in human plasma and urine
  236. Liver Disease in Diabetes Mellitus: Potential Therapeutic Value of Vitamin E-silybin Phytosomal Complex
  237. Liver Targeting Albumin-Coated Silybin-Phospholipid Particles Prepared by Nab™ Technology for Improving Treatment Effect of Acute Liver Damage in Intravenous …
  238. Liver-targeting self-assembled hyaluronic acid-glycyrrhetinic acid micelles enhance hepato-protective effect of silybin after oral administration
  239. Matrix metallopeptidase 9 targeted by hsa‐miR‐494 promotes silybin‐inhibited osteosarcoma
  240. Mechanism of Phospholipid Complex and its SNEDDS Enhancing the Oral Bioavailability of Silybin
  241. Mechanism of silybin action, III. Resorption of the flavonolignane derivative silybin into rat liver cells (author’s transl)
  242. Mechanism of silybin action, IV. Structure-action relationship (author’s transl)
  243. Mechanism of the antioxidant action of silybin and 2, 3-dehydrosilybin flavonolignans: a joint experimental and theoretical study
  244. Mechanism of the stimulation of RNA synthesis in rat liver nuclei by silybin
  245. Mechanism-Based Inhibitory and Peroxisome Proliferator-Activated Receptor α–Dependent Modulating Effects of silybin on Principal Hepatic Drug-Metabolizing …
  246. Mechanism-Based Inhibitory and PPARα-Dependent Modulating Effects of silybin on Principle Hepatic Drug-Metabolizing Enzymes
  247. Mechanisms of the Prevention and Treatment of Prostate Cancer by Silybin
  248. Media effects on the mechanism of antioxidant action of silybin and 2, 3-dehydrosilybin: Role of the enol group
  249. Meta-analysis of the Therapeutic Effect of Silybin-phospholipid Complex in the Treatment of Fatty Liver
  250. Metabolic and vascular effects of silybin in hypertensive patients with high 1-h post-load plasma glucose
  251. Metabolic fingerprinting to understand therapeutic effects and mechanisms of silybin on acute liver damage in rat
  252. Metabonomic Study of Hepato-protective Effect of silybin for the Carbon Tetrachloride Induced Liver Injure in Mice [J]
  253. Metal coordination protocol for the synthesis of-2, 3-dehydrosilybin and 19-O-demethyl-2, 3-dehydrosilybin from silybin and their antitumor activities
  254. Micellar liquid chromatographic determination of ribavirin, silybin, interferon α 2A, lamivudine, and ursodeoxycholic acid in dosage forms and biological fluids
  255. Microbial transformation of silybin by Trichoderma koningii
  256. Microfluidic fabrication of silybin nanodispersion with high dissolution rate and tunable sizes
  257. Micronization of silybin by the emulsion solvent diffusion method
  258. Milk Thistle Extract/Silymarin/Silybin
  259. Milk thistle’s active components silybin and isosilybin: novel inhibitors of PXR-mediated CYP3A4 induction
  260. Mixed micelles loaded with silybin-polyene phosphatidylcholine complex improve drug solubility
  261. Modulation of human polymorphonuclear leukocyte function by the flavonoid silybin.
  262. Modulatory effects of curcumin, silybin-phytosome and alpha-R-lipoic acid against thioacetamide-induced liver cirrhosis in rats
  263. Molecular and biochemical evidence on the protective role of ellagic acid and silybin against oxidative stress-induced cellular aging
  264. Molecular interaction of silybin with hyaluronidase: a spectroscopic and molecular docking study
  265. Molecular mechanisms of silybin and 2, 3-dehydrosilybin antiradical activity—role of individual hydroxyl groups
  266. Molecular Structure and Stereochemistry of silybin A, silybin B, Isosilybin A, and Isosilybin B, Isolated from Silybum marianum (Milk Thistle)
  267. Nanoemulsions as delivery systems of hydrophobic silybin from silymarin extract: effect of oil type on silybin solubility, in vitro bioaccessibility and stability
  268. Nanostructured calcium phosphate carriers for deliver of poor water-soluble drug silybin
  269. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies
  270. Narrow‐bore core–shell particles and monolithic columns in the analysis of silybin diastereoisomers
  271. New C-23 modified of silybin and 2, 3-dehydrosilybin: Synthesis and preliminary evaluation of antioxidant properties
  272. New derivatives of silybin and 2, 3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity
  273. New silybin scaffold for chemical diversification: Synthesis of novel 23-phosphodiester silybin conjugates
  274. Observation on efficacy of silybin capsule for chronic hepatitis B
  275. Observation on Efficacy of silybin Capsule in Treatment of Non-Alcoholic Fatty Liver [J]
  276. Optimisation of enzyme assisted extraction of silybin from the seeds of Silybum marianum by Box–Behnken experimental design
  277. Oxidation of the flavonolignan silybin. In situ EPR evidence of the spin-trapped silybin radical
  278. Oxidised derivatives of silybin and their antiradical and antioxidant activity
  279. Partially PEGylated PAMAM dendrimers as solubility enhancers of Silybin
  280. Peroxidase isoenzymes in cress seedlings (Lepidium sativum L.) and their inhibition by silybin, silydianin and silychristin
  281. Peroxyl Radical Scavenging Capacity of the Flavonolignan Silybin, Ginkgo Biloba Extract EGb 761, American Green Tea and a Series of Germacranolides
  282. Pharmacokinetic studies on IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects
  283. Pharmacokinetics and Tissue Distribution in Rats by Injection Use of silybin Meglumine Salt
  284. Pharmacokinetics and Tissue Distribution of silybin Gelatin Microspheres In vivo in Rats [J]
  285. Pharmacokinetics of pure silybin diastereoisomers and identification of their metabolites in rat plasma
  286. Pharmacokinetics of silybin A and silybin B in Rat by HPLC-MS/MS
  287. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction.
  288. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients.
  289. Pharmacokinetics of silybin nanoparticles in mice bearing SKOV-3 human ovarian carcinoma xenocraft
  290. Pharmacotherapy of Amanita phalloides poisoning using silybin
  291. Physicochemical characteristic and pharmacokinetics of silybin lipid microsphere [J]
  292. Phyto-liposomes as nanoshuttles for water-insoluble silybin–phospholipid complex
  293. Piperine enhances the bioavailability of silybin via inhibition of efflux transporters BCRP and MRP2
  294. Placental aldose reductase inhibition by silybin (preliminary communication).
  295. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers.
  296. Polyamidoamine dendrimers as potential drug carriers for enhanced aqueous solubility and oral bioavailability of silybin
  297. Polyporus Umbellalus Ploysaccharides and silybin in protecting ultrostructure of human fetal hepatocytes injured by CCL_4
  298. Positive effects of different drug forms of silybin in the treatment of metabolic syndrome
  299. Possible protective role of silybin against polymyxin E‐induced toxic effect in rat kidneys: A biochemical approach
  300. Potent direct or TNF-α-promoted anticancer effects of 2, 3-dehydrosilybin: Comparison study with silybin
  301. Preliminary clinical development of silipide: a new complex of silybin in toxic liver disorders
  302. Preparation and capability evaluation of oral microemulsion silybin
  303. Preparation and characterization of silybin-loaded nanostructured lipid carriers
  304. Preparation and evaluation of silybin nanocrystallines self-stabilizing Pickering emulsion
  305. Preparation and in vitro dissolution of silybin dispersible tablet
  306. Preparation and in vitro Release of silybin Gelatin Microsphere [J]
  307. Preparation and performance evaluation of emulsomes as a drug delivery system for silybin
  308. Preparation and properties of a silybin-phospholipid complex
  309. Preparation and Quality Control of silybin Meglumine Ophthalmic Gel
  310. Preparation and study on the in vitro release of silybin double-layer tablets
  311. Preparation of C-23 esterified silybin derivatives and evaluation of their lipid peroxidation inhibitory and DNA protective properties
  312. Preparation of hollow magnetic molecularly imprinted polymer and its application in silybin recognition and controlled release
  313. Preparation of self microemulsifying tablet for silybin phospholipid complex and its dissolution [J]
  314. Preparation of silybin 23-esters and evaluation of their inhibitory ability against LPO and DNA protective properties
  315. Preparation of silybin and isosilybin sulfates by sulfotransferase from Desulfitobacterium hafniense
  316. Preparation of silybin lipophilic derivatives and evaluation of their biological activities
  317. Preparation of silybin nanoemulsion and its pharmacokinetics in rabbits
  318. Preparation of silybin phase II metabolites: Streptomyces catalyzed glucuronidation
  319. Preparation of silybin submicron emulsion and study of its biodistribution in rats
  320. Preparation of silybin/poly (vinylpyrrolidone) nanodrugs by using the aerosol solvent extraction system for improving drug solubility
  321. Preparation of silybin-phosphatidylcholine compound and identification its physicochemical properties [J]
  322. Preparation of silybin-phospholipid complex and its bioavailability in rats
  323. Preparation of tritium‐labeled Silybin—a protectant for common liver diseases
  324. Preparation, characterisation and in vivo evaluation of silybin nanoparticles for the treatment of liver fibrosis
  325. Preparation, physico-chemical characterization and in vitro test of a Silybin–phospholipid complex encapsulated into liposomes.
  326. Preparative chromatographic purification of diastereomers of silybin and their quantification in human plasma by liquid chromatography–tandem mass spectrometry
  327. Prevention by silybin of phalloidin-induced acute hepatoxicity
  328. Prevention of praseodymium-induced hepatotoxicity by silybin
  329. Production of silybin-like compounds in cell suspension cultures of Silybum marianum
  330. Prophylactic administration of silybin ameliorates L-arginine-induced acute pancreatitis
  331. Prostate: a study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer
  332. Protective effect of silybin against verapamil-induced hepatotoxicity in rats
  333. Protective effect of silybin Capsules on hepatic injury induced by combining isoniazid with rifampin in mice
  334. Protective effect of silybin in rats liver toxicity
  335. Protective effect of silybin meglumine on rats with non-alcoholic fatty liver disease
  336. Protective Effect of Silybin-Phosphatidylcholine Compound on Acute Liver Damage Induced by Alpha-Naph-thylisothiocyanate in Mice
  337. Protective Effect of Silybin-phosphatidylcholine Compound on Acute Liver Injury Induced by CHCl_3 in Mice
  338. Protective effect of silybin-phosphatidylcholine compound on kidney in rats with diabetes [J]
  339. Protective effect of the flavonoid silybin dihemisuccinate on the toxicity of phenylhydrazine on rat liver
  340. Protective effects of S-adenosylmethionine (SAMe) and silybin on hepatorenal and hemostatic functions in dogs with endotoxemia
  341. Protective effects of silybin and analogues against X-ray radiation-induced damage
  342. Protective effects of silybin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion
  343. Protective effects of silybin Capsules on alcohol-induced hepatic fibrosis in rats
  344. Protective Effects of silybin on Cultured Cardiomyocytes with Deprivation of Oxygen and Glucose [J]
  345. Protective effects of silybin on human umbilical vein endothelial cell injury induced by H2O2 in vitro
  346. Protective effects of silybin-lecithin compound on cerebral ischemic-reperfusion Injury in rats [J]
  347. Protective effects of silybin-phosphatidylcholine compound on acute liver damage in mice induced by CCl~ 4
  348. Pulse radiolysis of silybin: one-electron oxidation of the flavonoid at neutral pH
  349. Quality standard and preliminary secure research on silybin powder for injection
  350. Quantitative estimation of silybin in Silybum marianum mother tincture using high performance liquid chromatography
  351. Rapid qualitative analysis of 2 flavonoids, rutin and silybin, in medical pills by direct analysis in real‐time mass spectrometry (DART‐MS) combined with in situ …
  352. Reactions of silybin, a flavonoid drug, with toxic free radicals
  353. Recent advances in the nanotechnology-based drug delivery of Silybin
  354. Regioselective alcoholysis of silybin A and B acetates with lipases
  355. Regioselective Formation of Silybin-23-β-D-Glucoside by Glucosylation of silybin with Cultured Plant Cells of Eucalyptus Perriniana
  356. Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer
  357. Relative bioavailability of silybin A and silybin B from 2 multiconstituent dietary supplement formulations containing milk thistle extract: A single-dose study
  358. Research on a kind of biocompatible molecularly imprinted materials with silybin controlled release based on pH/temperature dual responses
  359. Research on the Actions of silybin Disodium Hemisuccinate and Mono-(β-3-Ursolic Acid) Phthalate Disodium on the Primary Cultured Rat Hepatocytes
  360. Reversing effects of silybin on TAA-induced hepatic CYP3A dysfunction through PXR regulation
  361. Role of tangeretin as a potential bioavailability enhancer for silybin: Pharmacokinetic and pharmacological studies
  362. RP-HPLC Determination of silybin in Human Plasma
  363. Safety and bioavailability in Beagles of zinc and vitamin E combined with silybin and phosphatidylcholine
  364. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals
  365. Selective recognition and preliminary separation of hepatoprotective component silybin from milk thistle seeds by the prepared core–shell magnetic molecularly …
  366. Selective Synthesis of 3-O-Palmitoyl-Silybin, a New-to-Nature Flavonolignan with Increased Protective Action against Oxidative Damages in Lipophilic Media
  367. Self-assembly and characterization of Pluronic P105 micelles for liver-targeted delivery of silybin
  368. Separation and characterization of silybin, isosilybin, silydianin and silychristin in milk thistle extract by liquid chromatography–electrospray tandem mass spectrometry
  369. Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in …
  370. Short-term effect of silybin in capsule and~(131) I treatment in Graves patients with liver damage
  371. Significantly greater antioxidant anticancer activities of 2, 3-dehydrosilybin than silybin
  372. Silipide: a new bioavailable complex of silybin
  373. silybin (silibinin) structure and chirality
  374. silybin Against Liver Ischemia-Reperfusion Injury: Something Old, Something New…
  375. silybin alleviates hepatic steatosis and fibrosis in NASH mice by inhibiting oxidative stress and involvement with the Nf-κB pathway
  376. silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model
  377. silybin and 2, 3-dehydrosilybin flavonolignans as free radical scavengers
  378. silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins
  379. silybin and dehydrosilybin inhibit cytochrome P450 1A1 catalytic activity: a study in human keratinocytes and human hepatoma cells
  380. silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin
  381. silybin and metabolic disorders
  382. silybin and silymarin-new and emerging applications in medicine
  383. silybin and silymarin-new effects and applications
  384. silybin and the liver: from basic research to clinical practice
  385. silybin as therapeutic approach in an in vitro model of NAFLD
  386. silybin attenuates LPS-induced lung injury in mice by inhibiting NF-κB signaling and NLRP3 activation
  387. silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial
  388. silybin CONJUGATED WITH PHOSPHATIDYLCHOLINE AND VITAMIN E IMPROVES LIVER DAMAGE IN PATIENTS WITH NAFLD: THE RESULTS OF A …
  389. silybin content and overexpression of chalcone synthase genes in Silybum marianum L. plants under abiotic elicitation
  390. silybin counteracts doxorubicin resistance by inhibiting GLUT1 expression
  391. silybin counteracts lipid excess and oxidative stress in cultured steatotic hepatic cells
  392. silybin decreases erythrocytic sorbitol level and improves peripheral nerve conduction velocity in patients with non-insulin dependent diabetes mellitus
  393. silybin Derivatives Modulate Thyroid Hormone-Mediated UcP2 Expression in Neonatal Rat Cardiomyocytes
  394. silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver
  395. silybin dihemisuccinate protects rat erythrocytes against phenylhydrazine-induced lipid peroxidation and hemolysis
  396. silybin enhances mitochondrial function and inhibits NFkB activation in murine nonalcoholic fatty liver disease
  397. silybin exerts antioxidant effects and induces mitochondrial biogenesis in liver of rat with secondary biliary cirrhosis
  398. silybin from Silybum marianum seeds inhibits confluent-induced keratinocytes differentiation as effectively as retinoic acid without inducing inflammatory cytokine
  399. silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases
  400. silybin Induces Cell-Cycle Arrest and Inhibits Melanoma Cell Growth by Direct Targeting of MEK1/2 and RSK2
  401. silybin inhibition of amatoxin uptake in the perfused rat liver.
  402. silybin inhibition of human T-lymphocyte activation.
  403. silybin inhibits interleukin‐1β‐induced production of pro‐inflammatory mediators in canine hepatocyte cultures
  404. silybin inhibits migration of human hepatocellular carcinoma cells and its mechanism
  405. silybin inhibits NLRP3 inflammasome assembly through the NAD+/SIRT2 pathway in mice with nonalcoholic fatty liver disease
  406. silybin interacting with Cu4, Ag4 and Au4 clusters: do these constitute antioxidant materials?
  407. silybin is a direct antifibrogenic and antiinflammatory agent: Cellular and molecular mechanisms
  408. silybin is metabolized by cytochrome P450 2C8 in vitro
  409. silybin Modulates Collagen Turnover in an In Vitro Model of NASH
  410. silybin MONO-GALLATES AND THEIR ANTIANGIOGENIC ACTIVITY
  411. silybin nanoparticles for liver cancer: development, optimization and in vitro–in vivo evaluation
  412. silybin reduces lipid peroxidation of rat hepatocyte membrane caused by cyclosporin A
  413. silybin reduces obliterated retinal capillaries in experimental diabetic retinopathy in rats
  414. silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability
  415. silybin suppresses cell proliferation and induces apoptosis of multiple myeloma cells via the PI3K/Akt/mTOR signaling pathway
  416. silybin Synergizes with Wnt3a in Activation of the Wnt/β-catenin Signaling Pathway through Stabilization of Intracellular β-Catenin Protein
  417. silybin treatment is associated with reduction in serum ferritin in patients with chronic hepatitis C
  418. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells
  419. Silybin, a flavonolignan from milk thistle seeds, restrains the early and advanced glycation end product modification of albumin
  420. Silybin, a major bioactive component of milk thistle (Silybum marianum L. Gaernt.)—Chemistry, bioavailability, and metabolism
  421. Silybin, a new iron-chelating agent
  422. Silybin, a pharmacologically active constituent of Silybum marianum: fragmentation studies by atmospheric pressure chemical ionization quadrupole time‐of …
  423. Silybin/Silymarin treatment in chronic hepatitis C
  424. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent.
  425. Silybin-conjugated gold nanoparticles for antimicrobial chemotherapy against Gram-negative bacteria
  426. Silybin-derived flavonolignans and their structure-activity relationships: research advances.
  427. Silybin-Induced Apoptosis Occurs in Parallel to the Increase of Ceramides Synthesis and miRNAs Secretion in Human Hepatocarcinoma Cells
  428. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells
  429. Silybin–phosphatidylcholine complex protects human gastric and liver cells from oxidative stress
  430. Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin
  431. Silymarin and silybin in suppression of UVA-induced oxidative stress in normal human dermal fibroblasts
  432. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells
  433. SILYMARIN/silybin AGAINST CANCER
  434. Silymarin/silybin and chronic liver disease: a marriage of many years
  435. Simultaneous determination of silybin A and silybin B in rat plasma and pharmacokinetic study
  436. Simultaneous determination of silybin in shenqigankang capsules by RP-HPLC
  437. Simultaneous determination of silybin in shenqigankang capsules by RP-HPLC.
  438. Softgel capsule technology as an enhancer device for the absorption of natural principles in humans. A bioavailability cross-over randomised study on silybin.
  439. Solid Lipid Nanoparticles and Chitosan-coated Solid Lipid Nanoparticles as Promising Tool for silybin Delivery: Formulation, Characterization, and In vitro Evaluation
  440. Solubility of silybin in aqueous dextran solutions
  441. Solubility of silybin in aqueous hydrochloric acid solution
  442. Solubility of silybin in aqueous poly (ethylene glycol) solution
  443. Solubility of silybin in aqueous poly (vinylpyrrolidone) solution
  444. Spatial organization of silybin biosynthesis in milk thistle [Silybum marianum (L.) Gaertn]
  445. Spectrophotometric method for determination of flavone lignans and silybin in crude drug [in fruits] and its preparations from silybin marianum L.(Gaertn.)
  446. Stability‐indicating HPTLC method for quantitative estimation of silybin in bulk drug and pharmaceutical dosage form
  447. Stereoselective metabolism of silybin diastereoisomers in the glucuronidation process
  448. Stimulation by silybin, a eukaryotic feature of archaebacterial RNA polymerases
  449. Stimulation of RNA synthesis in rat liver and isolated hepatocytes by silybin, an antihepatotoxic agent from Silybum marianum L. Gaertn (author’s transl)
  450. Stimulierung der RNA-Synthese in Rattenleber und in isolierten Hepatozyten durch Silybin, einen antihepatotoxischen Wirkstoff aus Silybum marianum L. Gaertn.
  451. Structure and Solubility of Silybin-N-Meglumine.
  452. Structure of silybin: Synthetic studies
  453. Structure prerequisite for antioxidant activity of silybin in different biochemical systems in vitro
  454. Studies of the metabolism and excretion of silybin in the rat
  455. Studies on the active ingredient of Silybum marianum Gaertn–the extra ction, separation and identification of silybin
  456. Study and evaluation of preparation of silybin PLGA microspheres by stainless steel membrane emulsification technique
  457. Study of acute toxicity of silybin-lecithin compound
  458. Study of the electrochemical behavior of silybin
  459. Study on Dissolution Rate of silybin Tablets (Yiguanlin) Ⅱ. Preparation and Dissolution Study on Ground Compounds of Silybin-Hydrophilic Excipients
  460. Study on dissolution test method of silybin Solid Dispersion Capsules
  461. Study on preparation of silybin for injection
  462. Study on Quality Control of silybin Powder for Injection
  463. Study on the distribution of silybin lipid emulsion in the mice
  464. Study on the preparation and bio-distribution of silybin lipid nanospheres
  465. Study on the relation of structure and antioxidant activity of isorhamnetin, quercetin, phloretin, silybin and phloretin isonicotinyl hydrazone
  466. Substituent effects in the free radical reactions of silybin: radiation-induced oxidation of the flavonoid at neutral pH
  467. Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy …
  468. Superiority of flavonol 2, 3-dehydrosilybin than its parental silybin in inhibiting DNA topoisomerase I: An anti-cancer mechanism of 2, 3-dehydrosilybin
  469. Supersaturated polymeric micelles for oral silybin delivery: the role of the Soluplus–PVPVA complex
  470. Survey the effect of silybin on HER2 in SKBR3 breast cancer cell line
  471. Synergistic antibacterial effect between silybin and N,N′-dicyclohexylcarbodiimide in clinical Pseudomonas aeruginosa isolates
  472. Synthesis and antiangiogenic activity of new silybin galloyl esters
  473. Synthesis and antihepatotoxic activity of silybin 11-O-phosphate.
  474. Synthesis and antioxidant evaluation of novel silybin analogues
  475. Synthesis and antiproliferative activity of silybin conjugates with salinomycin and monensin
  476. Synthesis and chemical modification of poly (butylene succinate) with rutin useful to the release of silybin
  477. Synthesis of deuterium labeled silybin and isosilybin
  478. Synthesis of hypolipidemic silybin analog 3′, 4′-ethylenedioxyflavonoids.
  479. Synthesis of new silybin derivatives and evaluation of their antioxidant properties
  480. The absorption characteristics of silybin in small intestine of rat
  481. The action of silybin on the mouse liver in alpha-amanitine poisoning.
  482. The activity of silybin on phospholipid metabolism of normal and fatty liver in vivo
  483. The antioxidant silybin prevents high glucose-induced oxidative stress and podocyte injury in vitro and in vivo
  484. The blocking effects of silybin and quercetin on the nonenzymatic glycosylation of aortic collagen and serum β-Lp in experimental diabetic rats [J]
  485. The Clinical Observation of Curative Effects of Baoganjiangzhi Decoction in Combination with silybin for Fatty Liver Disease [J]
  486. The comparison between hepatoprotective effects of silybin-phosphatidylcholine compound and those of silybin against acute hepatic damage induced by carbon …
  487. The comparison of the effects of silybin and silybin-phosphatidylcholine on viability and ESR expression in human breast cancer T47D cell line
  488. The comparsion of silybin and silybin-phosphatidylcholine effects on viability, ESR1 and ESR2 expression in human breast cancer T47D cell line
  489. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study
  490. The effect of an iron (III) chelator, silybin, on the proliferation and cell cycle of Jurkat cells: a comparison with desferrioxamine
  491. The effect of silybin capsule in the treatment of non-alcoholic steatohepatitis
  492. The effect of silybin dihemisuccinate on cholesterol biosynthesis in rat liver homogenates (author’s transl)
  493. The Effect of silybin Micro-particle Dispersion on CCI_4 Induced Acute Liver Injury Mice
  494. The effect of silybin on lipid synthesis in ethanol-intoxicated rat hepatocytes in primary culture.
  495. The effect of silybin on liver phospholipid synthesis in the rat in vivo.
  496. The effect of silybin on passive avoidance learning and pathological changes in hippocampal CA1 and DG regions in male Wistar rats offspring
  497. The effect of silybin-dihemisuccinate on regulation disorders in phospholipid metabolism in acute galactosamine intoxication in the rat
  498. The effect of silybin-encapsulated micelle nanoparticles on mexY expression in ciprofloxacin-resistant isolates of Pseudomonas aeruginosa
  499. The effect of silymarin-N-methylglucamine salt and silybin-dihemisuccinate on (1-14C)-acetate incorporation in rat liver lipids (author’s transl)
  500. The effectiveness of silybin-phosphatidycholine compound on liver injury of mice induced by D-galn and BCG+ LPS
  501. The effects of mildewed food and silybin on the serum levels of thyriod hormons and IGF-Ⅰ in duckling [J]
  502. The effects of silybin on experimental phalloidine poisoning.
  503. The Effeet of Hyperbaric Oxygen Combined silybin in Treatment of Ischemia-Reperfusion-Induced Injury
  504. The efficiency and mechanism of N-octyl-O, N-carboxymethyl chitosan-based micelles to enhance the oral absorption of silybin
  505. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein
  506. The influence of silybin from Silybum marianum (L.) Gaertn. on in vitro phosphatidyl choline biosynthesis in rat livers.
  507. The influence of silybin on the hepatotoxic and hypoglycemic effects of praseodymium and other lanthanides.
  508. The iron-chelating potential of silybin in patients with hereditary haemochromatosis
  509. The natural flavonoid silybin improves the response to Photodynamic Therapy of bladder cancer cells
  510. The nutraceutic silybin counteracts excess lipid accumulation and Ongoing Oxidative stress in an In Vitro Model of non-alcoholic Fatty liver Disease …
  511. The preparation of silybin liposome by ethanol injection method and its quality evaluation
  512. The preparation of silybin–phospholipid complex and the study on its pharmacokinetics in rats
  513. The pros and the cons for the use of silybin-rich oral formulations in treatment of liver damage (NAFLD in particular)
  514. The protective effect of compound of silybin and phospholipid on hepatic damage induced by thioacetamide in rats
  515. The protective effect of silybin against lasalocid cytotoxic exposure on chicken and rat cell lines
  516. The protective effects of silybin on the cytotoxicity of thiram in human, rat and chicken cell cultures
  517. The role of silybin in inhibiting proliferation and promoting apoptosis of breast cancer cells
  518. THE SILYBIN-PHOSPHOLIPID COMPLEX IDB 1016 IN THE TREATMENT OF SEROLOGICAL RECURRENCE OF OVARIAN CANCER
  519. Therapeutic and antilipoperoxidant effects of silybin-phosphatidylcholine complex in chronic liver disease: Preliminary results
  520. Thermodynamic dissociation constants of silychristin, silybin, silydianin and mycophenolate by the regression analysis of spectrophotometric data
  521. Thermodynamic properties for the system of silybin and poly (ethylene glycol) 6000
  522. Total Synthesis of (±)-Silybin, an Antihepatotoxic Flavonolignan
  523. Total Synthesis of (i)-Silybin, an Antihepatotoxic Flavonolignan
  524. Treatment of Amanita phalloides poisoning with silybin in combination with penicillin and cortisone
  525. Treatment with silybin‐vitamin E‐phospholipid complex in patients with hepatitis C infection
  526. UVA-photoprotective potential of silymarin and silybin
  527. Water soluble poly (ethylene glycol) prodrug of silybin: design, synthesis, and characterization
  528. Zur Stereochemie von Silybin/The Stereochemistry of Silybin
Related Posts

Capsicum Annuum

Rottlerin

Carum Carvi (Caraway Seed)

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping